Imogam Rabies (Rabies Immune Globulin (Human)) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 16, 2022 Category: Drugs & Pharmacology Source Type: news
BayHep B (Hepatitis B Immune Globulin (Human)) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 2, 2022 Category: Drugs & Pharmacology Source Type: news
Antibody treatment for MIS-C works by depleting inflammatory immune cells
NIH-funded study explains how intravenous immune globulin helps children with rare COVID condition. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - October 15, 2021 Category: American Health Source Type: news
FDA approves Octapharma's Octagam ® 10% for adult dermatomyositis
(Yankee Public Relations) The U.S. Food and Drug Administration (FDA) has granted approval to Octapharma USA for Octagam ® 10% [Immune Globulin Intravenous (Human)], the first and only intravenous immunoglobulin (IVIg) to be indicated for the treatment of adult dermatomyositis, a rare immune-mediated inflammatory disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 20, 2021 Category: International Medicine & Public Health Source Type: news
FDA Approves Octapharma ’s Octagam 10% for Adult Dermatomyositis
PARAMUS, N.J.--(BUSINESS WIRE) July 20, 2021 --The U.S. Food and Drug Administration (FDA) has granted approval to Octapharma USA for Octagam® 10% [Immune Globulin Intravenous (Human)], the first and only intravenous immunoglobulin (IVIg) to be... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 20, 2021 Category: Drugs & Pharmacology Source Type: news
New study may offer treatment guidance for MIS-C
(Rutgers University) Children and adolescents with multisystem inflammatory syndrome in children (MIS-C) who are treated initially with intravenous immune globulin (IVIG) and glucocorticoids have reduced risk for serious short-term outcomes, including cardiovascular dysfunction, than those who receive an initial treatment of IVIG alone, a new study finds. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 12, 2021 Category: International Medicine & Public Health Source Type: news
Immunomodulation With IVIG, Glucocorticoids Examined in MIS-C
FRIDAY, June 25, 2021 -- The effectiveness of immunomodulation with intravenous immune globulin (IVIG), glucocorticoids, or both varies in multisystem inflammatory syndrome in children (MIS-C), according to results from two observational studies... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 25, 2021 Category: Pharmaceuticals Source Type: news
Study provides MIS-C treatment guidance
(Louisiana State University Health Sciences Center) An analysis conducted by a group of investigators including Tamara Bradford, MD, Associate Professor of Pediatrics at LSU Health New Orleans School of Medicine, found that children and adolescents with Multisystem inflammatory syndrome in children (MIS-C) initially treated with intravenous immune globulin (IVIG) plus glucocorticoids had a lower risk of new or persistent cardiovascular dysfunction than IVIG alone. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 22, 2021 Category: Infectious Diseases Source Type: news
FDA and CDC Recommend Pausing COVID-19 Vaccination With J & J-Janssen Shot While They Investigate Blood Clot Risks
The U.S. Food and Drug Administration and Centers for Disease Control and Prevention are recommending that vaccinations with the Johnson & Johnson/Janssen COVID-19 vaccine be temporarily halted while the agencies review reports of blood clots among vaccinated people.
On April 13, the two government agencies issued a joint statement announcing a recommended pause as federal regulators review six cases of blood clots reported six to 13 days after the people received the single-dose vaccine. “Until that [review] process is complete, we are recommending a pause in the use of this vaccine out of an abundance of cautio...
Source: TIME: Health - April 13, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
Two New Studies Point to How AstraZeneca ’s COVID-19 Vaccine Is Linked to Blood Clots
In two papers published in the New England Journal of Medicine (NEJM), researchers in Europe provide the most detailed explanation yet for what is behind the clotting side effects reported among people getting vaccinated with the AstraZeneca COVID-19 shot.
In both papers, researchers found that people getting the vaccine had higher levels of antibodies directed against a cluster of immune-related cells that the body might form in response to the vaccine. These clusters include platelets, which help blood to clot when you get cut or injured, and the antibodies stick to the platelet-complex and form dangerous clots that can ...
Source: TIME: Health - April 9, 2021 Category: Consumer Health News Tags: Uncategorized COVID-19 Source Type: news
Home Subcutaneous Immune Globulin for Refractory Dermatomyositis Home Subcutaneous Immune Globulin for Refractory Dermatomyositis
' The technology is there. I think our patients might feel more comfortable getting immune globulin at home, ' says Dr Postolova, a rheumatologist and allergist/immunologist.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 19, 2021 Category: Consumer Health News Tags: Rheumatology News Source Type: news
Rabies treatment demonstrated as safe and effective for use in children in first pediatric trial
(Taylor& Francis Group) A treatment, known as KEDRAB (Rabies Immune Globulin [Human]), currently used in the prevention of rabies has been demonstrated to be safe and effective for patients age 17 and under. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 10, 2021 Category: Biology Source Type: news
Octapharma launches phase 3 study for pediatric acute-onset neuropsychiatric syndrome
(Yankee Public Relations) Octapharma has launched a phase 3, multicenter superiority study to compare the ef-fectiveness of PANZYGA ® (immune globulin intravenous, human - ifas) 10% Liquid Preparation versus placebo in patients with pediatric acute-onset neuropsychiatric syndrome (PANS). (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - September 3, 2020 Category: International Medicine & Public Health Source Type: news
FDA approves Octapharma USA IND application for severe COVID-19 patients
(Yankee Public Relations) The US Food and Drug Administration (FDA) has approved the investigational new drug (IND) application submitted by Octapharma USA for a phase three clinical trial on the efficacy and safety of Octagam 10% [Immune Globulin Intravenous (Human)] therapy in COVID-19 patients with severe disease progression. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 20, 2020 Category: Infectious Diseases Source Type: news
HIZENTRA(R) (Immune Globulin Subcutaneous [Human] 20% Liquid) Receives Orphan-Drug Exclusivity for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
First and only subcutaneous immunoglobulin (SCIg) approved for maintenance therapy in CIDP qualifies for marketing exclusivity
KING OF PRUSSIA, Pa., Dec. 9, 2019 -- (Healthcare Sales & Marketing Network) -- Global biotherapeutics leader CSL Behring ann... Biopharmaceuticals, Neurology, FDA CSL Behring, HIZENTRA, Immune Globulin, Demyelinating Polyn (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 9, 2019 Category: Pharmaceuticals Source Type: news
